Project Grant R01CA290188
Award Date
6/15/24
Completion Date
5/31/29
Dollars Obligated
$1.1M
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02139, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $158,020 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The grant, awarded on August 18, 2025, supports research to investigate the role of mutagenic DNA repair pathways, such as microhomology-mediated end joining (MMEJ), in driving acquired drug resistance in persister cancer cells. Specifically, the project aims to (1) study persistence mechanisms in BRCA1/2-mutant cancer...
The National Cancer Institute (NCI) awarded a $487,393 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research in New York, NY. The grant funding will support research to determine the role of key proteins like RAD52, HELQ, and POLQ in the backup repair of DNA double-strand breaks within homologous recombination deficient (HRD) cancers. The researchers aim to evaluate the relative contribution of these proteins to...
This Project Grant award from the National Institute of Environmental Health Sciences (NIEHS), under the Environmental Health (CFDA 93.113) program, is aimed at developing an innovative approach to mutational fingerprinting of environmental exposures. The primary goals are to: Quantify the levels of circulating cell-free DNA (cfDNA) in blood after treatment with two different environmental hepatocarcinogens, aflatoxin B1 (AFB1) and N-nitrosodimethylamine (NDMA), to determine the temporal...
This Project Grant award of $942,442 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research by the Dana-Farber Cancer Institute (DFCI) to identify the mechanisms driving the rapid evolution of cancer genomes. The key objectives are to understand the processes of chromothripsis, a catastrophic mutational event involving massive chromosome rearrangement, and chromoplexy, another poorly understood mutational process common in cancer. Using...
The National Cancer Institute (NCI) awarded a $1,334,043 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The grant supports a 5-year research project to decipher the functions of the ATR-METTL3-BRCA1 axis in genome instability and tumorigenesis, with the goal of revealing new insights into DNA repair mechanisms and identifying therapeutic targets for triple-negative breast...
This Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program will support the development of high-throughput functional assays and analytical frameworks to measure DNA repair capacity across all major pathways at single-cell resolution. The $390,366 award to the Broad Institute of MIT and Harvard will enable the creation of a library of DNA repair reporter plasmids that can signal repair activity through...
This $1,063,710 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The grant will fund research conducted by The Johns Hopkins University to investigate the epigenetic mechanisms controlling sensitivity to single-stranded DNA lesions and associated mutagenesis. The primary objectives are to define the role of the histone variant MacroH2A1 in regulating DNA repair processes, determine the impact on cancer risk and...
The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...
The National Cancer Institute (NCI) awarded a $224,100 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Maryland, Baltimore (UMB) to investigate the role of the neddylation process in repairing topoisomerase I (TOP1) inhibitor-induced DNA damage in colorectal cancer. The research aims to systematically assess how the DDB1-CUL4-RBX1 ubiquitin ligase complex, which is activated by neddylation, ubiquitylates and degrades TOP1-DNA protein crosslinks, thereby promoting...
This $749,474 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Beth Israel Deaconess Medical Center, Inc. (Bidmc) supports scientific research to elucidate the underlying processes of failed resolution of inflammation initiated by environmental chemicals. The study aims to profile lipid autacoid mediators and cytokines to evaluate pro-resolving lipid mediators as interventional targets in chemical-induced cancer. The research will also investigate...